merck glp-1 moves into obesity with deal for Hansoh's pill merck glp 1 agonist Emerging
Description
[DOI] [PubMed] [Google Scholar] 112.Evert A.B., Dennison M., Gardner C.D., Garvey W.T., Lau K.H.K., MacLeod J., et al
In a study of diabetic patients, exenatide was found to transiently suppress the expression of inflammatory markers TNF and IL-1
The semaglutide group had increased CTX-1, with an estimated difference of 166.4 g/L (p = 0.021), and reduced BMD in the lumbar spine (ETD: -0.018 g/cm
After one half-life, 50% remains
When it occurs with GLP-1 agonists, it is usually related to rapid weight loss and caloric restriction at higher therapeutic doses, not to the peptide itself
How would you answer this patient about realistic weight-loss goals while using this medication
